Thursday, May 16, 2013

Actavis eying Nasonex Generics - Initiates Phase 3 trial

Actavis (Watson) has initiated a double-blind, randomized, placebo-controlled, parallel group, multi-site Study to compare the clinical equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis. The study will enroll 875 patients in the US and is expected to complete in September 2013.

Nasonex is marketed by Merck and patent will expire on  July 27, 2014. Nasonex generated worldwide annual sales of $1.3billion in 2012. In the US, sales were $600m

Enter your email address:

Delivered by FeedBurner